The Healing Properties of Rapamycin as Revealed by Mikhail Blagosklonny

Dr. Mikhail’s role as a researcher, philanthropist, and professor has seen him draw attention from scores of students and stakeholders in the cancer treatment. Blagosklonny aims at finding safer and more effective treatments for cancer patients at all economic levels through the use of Rapamycin.Mikhail Blagosklonny has also extended his interests into aging and has been an advocate for the use of Rapamycin, also known as Sirolimus, to extend human life. Blagosklonny serves as a professor of oncology at Roswell Park Cancer Institute in New York and also serves as the editor-in-chief for Aging, Cell Cycle, and Oncotarget.

Why is Rapamycin important?

Rapamycin contains immunosuppressive properties that are used in the treatment of transplant patients. The body rejects transplant organs, and treatment with immunosuppressive drugs comes with further toxicity to the kidneys. Rapamycin, however, is less toxic to the kidneys and is, therefore, a suitable immunosuppressant for transplant patients. The low toxicity of Rapamycin to the kidneys also makes it effective in treating the hemolytic-uremic syndrome, a rare disease that is a combination of kidney failure, anemia, and low platelet count.In addition, Rapamycin is the primary drug used in the treatment of Lymphangioleiomyomatosis (LAM), a rare lung disease that occurs among women of childbearing age. The use of Sirolimus has also been extended to coronary stent coating. Patients that have used Rapamycin have shown a lower rate of re-occurrence of re-stenosis in the arteries after undergoing balloon angioplasty.When taken in the right dosages, the antiproliferative properties of Rapamycin reduce the cancer risk in transplant patients.

The drug has a capacity of enhancing the body’s immune responses towards tumors and promotes tumor regression. Through improving the body’s immune response towards tumors, Sirolimus can also be used in treating Tuberous Sclerosis Complex (TSC). Studies showed that the benign tumors in TSC patients started to regrow once Rapamycin treatment was stopped.With regards to longevity of life, Dr. Mikhail firmly believes that Rapamycin can be used to slow down aging. During tests conducted on mice, the use of Rapamycin in aging mice improved their ability to deal with tuberculosis. Though the evidence is inconclusive, earlier tests on human beings exhibited immunological rejuvenation among elderly patients who received dosages on Sirolimus prior to influenza vaccination. Currently, there are ongoing tests on the marmoset monkey to prove the longevity theory.Further research into more devastating illnesses such as Muscular Dystrophy, Systemic Lupus Erythematosus (SLE), and Alzheimer’s disease is still in progress. Rapamycin has yielded positive results in all cases, and there is hope that the drug could be a possible cure for the aforementioned illnesses.


Mikhail Blagosklonny hopes to find ways to treat cancer without destroying normal cells required in recovery, and also cure fatal illnesses as mentioned above. His passion in his field of research continues to inspire many who will hopefully pick up when he stops. Rapamycin has shown positive results towards treating many rare and fatal diseases, and hopefully, more research will yield conclusive results in treating cancer and dealing with aging among human beings.

Eric Lefkofsky is working to improve the lives of others

The rate at which cancer is spreading is very worrying. With that said, Eric Lefkofsky decided to help the medical industry out after his wife was diagnosed with cancer. He co-founded Tempus which was in charge of coming up with a platform where the data collected in hospitals could be analyzed in a structured manner to help the cancer patients access better and accurate treatment. This company was focused on enabling the use of data to come up with medicine.

Lots of data had been collected about patients but it was not been utilized fully. Most of it was physically recorded. Eric, at Tempus, came up with a software that was able to capture this information and store it in a structured manner so that could be used to find the most appropriate treatment for patients. In the market at the time, it was difficult to make good use of the data that had been collected because it was not centralized and comprehensive. Eric assisted in streamlining this data to make it efficient for use.

He believes that soon doctors will be able to come up with cures for diseases such as cancer through the use of structured data. He further states that if clinical and molecular data are combined and analyzed intensively the secret behind critical diseases such as cancer can be found and treatment secured. With the data being updated in real time, patients will be able to receive informed treatment solutions from their doctors through analysis of their gathered data and progress reports.

Eric Lefkofsky was born and bred in Michigan. He is a lawyer by profession although he hardly involves himself in that field of work. He is a Juris Doctor graduate of the University of Michigan Law School. Prior to this achievement, he had graduated from the University of Michigan in 1991. He later relocated to Chicago to further his career at Tempus where he holds the Chief Executive Officer position. He is continuously working on advancing the analytic platform at Tempus in order to assist people to get precise medicine for their diseases.

Eric has worked for many institutions and companies including the Art Institute of Chicago, Chicago’s Steppenwolf Theatre Company, Lurie’s Children’s Memorial Hospital, Northwestern University’s Kellogg School of Management and the University of Chicago’s Booth School of Business among others. He has held different positions in these places.